GAITHERSBURG, Md., Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...

WAKE COUNTY, N.C. (WTVD) -- A fourth vaccine could soon be added to the arsenal of weapons against the novel Coronavirus. Triangle residents played a role in the successful trials of the Novavax ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...

Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...

Sept 15 (Reuters) - U.S. drug developer Novavax Inc (NVAX.O), opens new tab said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...